Cardiomyocyte Proliferative Capacity Is Restricted in Mice With Lmna Mutation.

Area of Science:

• Cardiovascular Genetics
• Cell Biology
• Molecular Medicine

Background:

• Dilated cardiomyopathy (DCM) is often inherited, with mutations in the LMNA gene being a significant cause.
• Unlike other DCM genes, LMNA encodes nuclear proteins (lamin A/C) not directly involved in muscle contraction.
• The precise molecular mechanisms linking LMNA mutations to DCM remain poorly understood.

Purpose of the Study:

• To elucidate the mechanism by which LMNA mutations lead to the development of DCM.
• To investigate the impact of LMNA mutations on cardiomyocyte proliferation and cell cycle activity.

Main Methods:

• Assessed cardiomyocyte phenotypes and cell cycle activity in mice with Lmna mutations.
• Utilized RNA-sequencing and pathway analysis to identify affected cellular processes.
• Confirmed protein expression changes (p21) via Western blot and immunostaining.
• Evaluated cardiomyocyte proliferative capacity following cardiac apex resection in neonate mice.

Main Results:

• Lmna mutant mice exhibited reduced cardiomyocyte number and size, with immature cells and retarded cell cycle activity.
• RNA-sequencing identified impaired cell proliferation as a key impact of Lmna mutation.
• The cell cycle inhibitor gene Cdkn1a (encoding p21) was significantly upregulated in Lmna mutants.
• Increased DNA damage was observed in Lmna mutant mice, correlating with Cdkn1a upregulation.
• Mutant mice showed restricted cardiomyocyte proliferation capacity after injury.

Conclusions:

• Loss of lamin A/C function impairs cardiomyocyte proliferation through cell cycle defects.
• Inadequate intrinsic or responsive proliferation capacity is crucial in the pathogenesis of LMNA-associated DCM.
• These findings highlight a novel mechanism involving nuclear envelope protein dysfunction in DCM development.